OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine
Anna Pira, Jo Linda Sinagra, Francesco Moro, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 8
Anna Pira, Jo Linda Sinagra, Francesco Moro, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 8
Showing 8 citing articles:
The Unseen Aftermath: Associations Between the COVID-19 Pandemic and Shifts in Mortality Trends in Japan
Hasan Jamil, Shuhei Nomura, Stuart Gilmour
International Journal of Environmental Research and Public Health (2025) Vol. 22, Iss. 1, pp. 74-74
Open Access
Hasan Jamil, Shuhei Nomura, Stuart Gilmour
International Journal of Environmental Research and Public Health (2025) Vol. 22, Iss. 1, pp. 74-74
Open Access
Associated factors related to production of autoantibodies and dermo-epidermal separation in bullous pemphigoid
Li Yang, Yulu Wang, Ya‐Gang Zuo
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
Li Yang, Yulu Wang, Ya‐Gang Zuo
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
Pemphigus: trigger and predisposing factors
Francesco Moro, Jo Linda Sinagra, Adele Salemme, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 10
Francesco Moro, Jo Linda Sinagra, Adele Salemme, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 10
COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid
Anna Pira, Feliciana Mariotti, Francesco N. Moro, et al.
Vaccines (2024) Vol. 12, Iss. 9, pp. 1016-1016
Open Access | Times Cited: 1
Anna Pira, Feliciana Mariotti, Francesco N. Moro, et al.
Vaccines (2024) Vol. 12, Iss. 9, pp. 1016-1016
Open Access | Times Cited: 1
Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia
Ben Koszegi, Corey Stone, Dédée F. Murrell
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 2
Ben Koszegi, Corey Stone, Dédée F. Murrell
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 2
Response: Commentary: Bullous pemphigoid associated with COVID-19 vaccines: An Italian multicenter study
Anna Pira, Chiara Moltrasio, Damiano Abeni, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 2
Anna Pira, Chiara Moltrasio, Damiano Abeni, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 2
COVID-19 Outcomes in Patients with Autoimmune Bullous Dermatoses: A Comparative Study of Pemphigus Vulgaris and Bullous Pemphigoid
Maryam Sadat Sadati, Marzieh Alizadeh, Fardin Karbakhsh Ravari, et al.
Research Square (Research Square) (2024)
Open Access
Maryam Sadat Sadati, Marzieh Alizadeh, Fardin Karbakhsh Ravari, et al.
Research Square (Research Square) (2024)
Open Access
Dramatic deterioration or new‐onset dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid after COVID‐19 vaccination: A possible manifestation of immune reconstitution inflammatory syndrome
Midori Sunada, Seiko Sugiyama, Yukiko Nakahara, et al.
JEADV Clinical Practice (2023) Vol. 2, Iss. 3, pp. 479-487
Open Access
Midori Sunada, Seiko Sugiyama, Yukiko Nakahara, et al.
JEADV Clinical Practice (2023) Vol. 2, Iss. 3, pp. 479-487
Open Access
